

**This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.**

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

**For more information on the Reference Group, please go to:**  
**[www.IDURefGroup.Com](http://www.IDURefGroup.Com)**

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
<b>1. Needle and syringe programs (NSPs)</b>	<b>5</b>
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
<b>2. Opioid substitution programs (OST)</b>	<b>10</b>
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

<b>Section</b>	<b>Page</b>
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
<b>3. Other Drug Treatment (ODT)</b>	<b>23</b>
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
<b>4. HIV testing and counselling (T&amp;C)</b>	<b>40</b>
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

<b>Section</b>	<b>Page</b>
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
<b>5. Anti-retro-viral (ARV) treatment</b>	<b>43</b>
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
<b>6. Condoms</b>	<b>46</b>
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

## Poland (Eastern Europe)

### Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	NK	NK	NK
Year of IDU prevalence estimate			
Reference for IDU prevalence estimate	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.</p> <p>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.</p>		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	NK	NK	NK
Year of HIV prevalence among IDU estimate	2006		
Reference for HIV prevalence among IDU estimate	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age in 2008	27 230 442 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	NK	NK	NK
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	NK	NK	NK

## 1. Needle and syringe programs (NSPs)

### NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other NSP indicators
When were NSPs first introduced?	1991
Reference	Krajowe Centrum ds. AIDS (2008). Report on implementation of UNGASS Declaration of Commitment on HIV/AIDS in Poland. Warsaw, National Centre AIDS, Agenda of the Ministry of Health: 16.
Are needles and syringes available for purchase from pharmacies?	
Most recent year of documentation	
Reference	

### NSP 2: Number of NSP sites

Data reported	27 NSP sites		
Year of reported data	2008		
Reference	Malczewski, A. Reitox National Focal Point National Bureau for Drug Prevention Poland. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	27		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

## NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	3101 IDUs accessed NSPs		
Year of reported data	2008		
Reference	Malczewski, A. Reitox National Focal Point National Bureau for Drug Prevention Poland. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	3101		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	NK	NK	NK

## NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	43 323 contacts with NSPs		
Year of reported data	2008		
Reference	Malczewski, A. Reitox National Focal Point National Bureau for Drug Prevention Poland. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	43 323		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	NK	NK	NK

## NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

<b>Data reported</b>	31 8054 syringes and 432 720 needles distributed		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Malczewski, A. Reitox National Focal Point National Bureau for Drug Prevention Poland. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
<b>Adjustments</b>	Smaller count taken as per decision rule of this review		
<b>Final/Adjusted data (to be used as indicator numerator)</b>	318 054		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	27 230 442 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

**NSP: All documents reviewed**

Aceijas, C., M. Hickman, et al. (2007). "Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia.[see comment]." *Addiction* 102(8): 1244-50.

Bukowska, B., et al, and Reitox National Focal Point (2006). Poland: New Developments, Trends and In-depth Information on Selected Issues. National Report to the EMCDDA.

Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.

Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." *Statistical Bulletin* Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." *Statistical Bulletin* 2009, from <http://www.emcdda.europa.eu/stats09/hsr>.

Grzegorz Wodowski Poland (2008). The METHWORK program. Reference Group to the UN on HIV and Injecting Drug Use. Krakow.

Harm Reduction Center (2008). Statistics from period 1996-2008, Krakow.

Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.

Jurgens, R. and G. Betteridge (2005). "Prisoners who inject drugs: public health and human rights imperatives." *Health & Human Rights* 8(2): 46-

Krajowe Centrum ds. AIDS (2008). Report on implementation of UNGASS Declaration of Commitment on HIV/AIDS in Poland. Warsaw, National Centre AIDS, Agenda of the Ministry of Health: 16.

Malczewski, A. Reitox National Focal Point National Bureau for Drug Prevention Poland. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.

Ptaszek, G. (2007). HIV/AIDS: the Polish policy 1985-2005. Warsaw, National AIDS Centre.

Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

Sarang, A., R. Stuijkyte, et al. (2007). "Implementation of harm reduction in Central and Eastern Europe and Central Asia." *International Journal of Drug Policy* 18(2): 129-35.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

**2. Opioid substitution treatment (OST)****OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was agonist OST first available?	1992 - 1995
Reference	Gryn, K. Specialist Substitution Programs. Personal Communication: SMT Poland. 2008. Received by the Reference Group to the UN on HIV and Injecting Drug Use - Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network.  European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from <a href="http://www.emcdda.europa.eu/stats09/hsr">http://www.emcdda.europa.eu/stats09/hsr</a> .

**OST 2: Availability of methadone maintenance treatment (MMT)**

Is MMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was MMT first available?	1993
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from <a href="http://www.emcdda.europa.eu/stats09/hsr">http://www.emcdda.europa.eu/stats09/hsr</a> .

**OST 3: Availability of buprenorphine maintenance treatment (BMT)**

Is BMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was BMT first available?	
Reference	

**OST 4: Availability of other forms of agonist OST**

Are other forms of OST available?	
Comments	
Most recent year of documentation	
Reference	
When were other forms of OST first available?	
Reference	

## OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	80 mg
Comments	
Year	2009
Reference	World Health Organisation (2009). Global health ATLAS data.
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

## OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	8 mg
Comments	
Year	2009
Reference	World Health Organisation (2009). Global health ATLAS data.
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

## OST 7: Total number of all sites providing OST

Data reported	22 MMT sites 3 BMT sites		
Year of reported data	2009		
Reference	Gryn, K. (Specialist Substitution Programs), National Bureau of Drug Prevention. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Warsaw, Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments	Assumed counts not mutually exclusive		
Final/Adjusted data (to be used as indicator numerator)	22		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 287 709 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## OST 8: Number of sites providing MMT

Data reported	17 community sites and 5 prisons		
Year of reported data	2009		
Reference	Gryn, K. (Specialist Substitution Programs), National Bureau of Drug Prevention. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Warsaw, Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	22		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 287 709 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## OST 9: Number of sites providing BMT

Data reported	3 BMT sites		
Year of reported data	2009		
Reference	Gryn, K. (Specialist Substitution Programs), National Bureau of Drug Prevention. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Warsaw, Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	3		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 287 709 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## OST 11: Number of all clients in any OST at a single point in time

Data reported	1450 patients in SMT [No information on whether number of clients in OST at single point in time (i.e. Census date) or total number of clients receiving OST over a period of time]		
Year of reported data	2008		
Reference	Gryn, K. Specialist Substitution Programs. Personal Communication: SMT Poland. 2008. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments	Assumed enrolment at a census date		
Final/Adjusted data (to be used as indicator numerator)	1450		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 12: Number of all clients in MMT at a single point in time

Data reported	1200 patients on MMT		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	1200		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 287 709 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 13: Number of all clients in BMT at a single point in time

Data reported	BMT available but number of clients not known		
Year of reported data	2009		
Reference	Gryn, K. (Specialist Substitution Programs), National Bureau of Drug Prevention. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Warsaw, Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 287 709 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 14: Number of all clients in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008		
Reference	Gryn, K. Specialist Substitution Programs. Personal Communication: SMT Poland. 2008. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

## OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008		
Reference	Gryn, K. Specialist Substitution Programs. Personal Communication: SMT Poland. 2008. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

## OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2009		
Reference	Gryn, K. (Specialist Substitution Programs), National Bureau of Drug Prevention. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Warsaw, Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 287 709 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

## OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High
	NK	NK	NK

## OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	1450 patients in SMT [No information on whether number of clients in OST at single point in time (i.e. Census date) or total number of clients receiving OST over a period of time]		
Year of reported data	2008		
Reference	Gryn, K. Specialist Substitution Programs. Personal Communication: SMT Poland. 2008. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments	Assumed count equal to total number of clients enrolled in OST throughout 2008		
Final/Adjusted data (to be used as indicator numerator)	1450		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	MMT available but number of clients not known		
Year of reported data	2008		
Reference	Gryn, K. Specialist Substitution Programs. Personal Communication: SMT Poland. 2008. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	BMT available but number of clients not known		
Year of reported data	2009		
Reference	Gryn, K. (Specialist Substitution Programs), National Bureau of Drug Prevention. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Warsaw, Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 287 709 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008		
Reference	Gryn, K. Specialist Substitution Programs. Personal Communication: SMT Poland. 2008. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

## OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008		
Reference	Gryn, K. Specialist Substitution Programs. Personal Communication: SMT Poland. 2008. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

## OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2009		
Reference	Gryn, K. (Specialist Substitution Programs), National Bureau of Drug Prevention. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Warsaw, Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 287 709 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

## OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High
	NK	NK	NK

**OST: All documents reviewed**

BISDRO University of Bremen and WIAD Scientific Institute of the German Medical Association Bonn (2008). Reduction of Drug-related Crime in Prison: The impact of opioid substitution treatment on the manageability of opioid dependent prisoners.

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Bukowska, B., et al, and Reitox National Focal Point (2006). Poland: New Developments, Trends and In-depth Information on Selected Issues. National Report to the EMCDDA.

Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.

Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.

European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." Statistical Bulletin Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from <http://www.emcdda.europa.eu/stats09/hsr>.

Gryn, K. Specialist Substitution Programs. Personal Communication: SMT Poland. 2008. Received by the Reference Group to the UN on HIV and Injecting Drug Use

Gryn, K. (Specialist Substitution Programs), National Bureau of Drug Prevention. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". Warsaw, Poland, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 15 May 2009.

Grzegorz Wodowski Poland (2008). The METHWORK program. Reference Group to the UN on HIV and Injecting Drug Use. Krakow.

International Harm Reduction Development Program (2008). Harm reduction developments 2008. New York.

Jurgens, R. (2007). Interventions to address HIV in prisons: drug dependence treatments. Evidence for action technical papers. Geneva, World Health Organisation (WHO).

Krajowe Centrum ds. AIDS (2008). Report on implementation of UNGASS Declaration of Commitment on HIV/AIDS in Poland. Warsaw, National Centre AIDS, Agenda of the Ministry of Health: 16.

Poland (2007). On the specific mode of conduct for the treatment of substitution and the specific conditions that should satisfy the health care establishment carrying out the substitution treatment.

Ptaszek, G. (2007). HIV/AIDS: the Polish policy 1985-2005. Warsaw, National AIDS Centre.

Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

Sarang, A., R. Stuikyte, et al. (2007). "Implementation of harm reduction in Central and Eastern Europe and Central Asia." International Journal of Drug Policy 18(2): 129-35.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

Wodowski, G. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Poland". 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use.

**3. Other drug treatment (ODT)****ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	30 detoxification wards & subwards		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	30		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 131 254 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## ODT 1.2: Number of IDUs receiving detoxification

<b>Data reported</b>	Detoxification available but number not known		
<b>Year of reported data</b>	2007		
<b>Reference</b>	Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	27 131 254 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs in detoxification in a 12 month period</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs in detoxification at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

### ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

<b>Data reported</b>	Detoxification available but number not known		
<b>Year of reported data</b>	2007		
<b>Reference</b>	Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	Low	Mid	High
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	27 131 254 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs</b>	Low	Mid	High
	NK	NK	NK

## ODT 2 - Residential rehabilitation

## ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## ODT 2.2: Number of IDUs in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	NK	NK	NK

## ODT 2.3: Number of all clients in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

## ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

## ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	Yes		
Number of sites - data reported	84 psychoactive substance prevention, treatment and rehabilitation centres		
Year of reported data	2006		
Reference	Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	84		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 014 303 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

### ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

<b>Data reported</b>	Psychosocial support and counselling present but number not known		
<b>Year of reported data</b>	2006		
<b>Reference</b>	Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	Low	Mid	High
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	27 014 303 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time</b>	Low	Mid	High
	NK	NK	NK

### ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

<b>Data reported</b>	Psychosocial support and counselling present but number not known		
<b>Year of reported data</b>	2006		
<b>Reference</b>	Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	Low	Mid	High
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	27 014 303 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs</b>	Low	Mid	High
	NK	NK	NK

## ODT 4 - Peer-based support groups

## ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	74 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	74		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 230 442 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

## ODT 4.3: Number of all clients in peer-based support groups

<b>Data reported</b>	Narcotics Anonymous present but number not known		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	27 230 442 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	null	null

## ODT 5 - Drug treatment (treatment type not specified)

## ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available	In-patient treatment - type not specified		
Number of sites - data reported	358 inpatient units outpatient units not reported		
Year of reported data	2006		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from <a href="http://www.emcdda.europa.eu/stats09/tdi">http://www.emcdda.europa.eu/stats09/tdi</a> .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	>=358		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 014 303 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

<b>Data reported</b>	Drug treatment present but number of IDUs receiving treatment not reported		
<b>Year of reported data</b>	2006		
<b>Reference</b>	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from <a href="http://www.emcdda.europa.eu/stats09/tdi">http://www.emcdda.europa.eu/stats09/tdi</a> .		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	27 014 303 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

## ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

<b>Data reported</b>	13 198 clients entering treatment at 358 inpatient treatment units		
<b>Year of reported data</b>	2006		
<b>Reference</b>	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from <a href="http://www.emcdda.europa.eu/stats09/tdi">http://www.emcdda.europa.eu/stats09/tdi</a> .		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	13 198		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	27 014 303 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

## ODT 6 - Drug treatment in prisons

## ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

## ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

## ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

## ODT 7 - Compulsory detention as response to drug use

## ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High
	NK	NK	NK

## ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	

## ODT: All documents reviewed

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Bukowska, B., et al, and Reitox National Focal Point (2006). Poland: New Developments, Trends and In-depth Information on Selected Issues. National Report to the EMCDDA.

European monitoring Centre for Drugs and Drug Addiction. (2008). "Treatment demand indicator - Statistical bulletin " Statistical Bulletin Retrieved 6 April, 2009, from [http://www.emcdda.europa.eu/html.cfm/index65250EN.html?type=stats&stat\\_category=w100&stat\\_type=w87&order=stat\\_reference&CFID=5203606&CFTOKEN=161d43f9a7fd61fb-2D894FE8-E64D-EF3F-72C0BF31D6EAF23A&jsessionid=3830aef6e3d5cdb788212d644b714373741b](http://www.emcdda.europa.eu/html.cfm/index65250EN.html?type=stats&stat_category=w100&stat_type=w87&order=stat_reference&CFID=5203606&CFTOKEN=161d43f9a7fd61fb-2D894FE8-E64D-EF3F-72C0BF31D6EAF23A&jsessionid=3830aef6e3d5cdb788212d644b714373741b).

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from <http://www.emcdda.europa.eu/stats09/tdi>.

Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

Reitox National Focal Point (2008). Poland - New developments, trends and in-depth information on selected issues 2008 National report (2007 data) to the EMCDDA,.

## 4. HIV testing and counselling (T&C)

### T&C 1: Availability of HIV T&C

Is T&C available?	Yes
Most recent year of data	2008
Reference	See references for other VCT indicators

### T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

### T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	21 sites		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	21		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 131 254 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## T&amp;C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High
	NK	NK	NK

## T&amp;C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	2007
Reference	UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362. WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.
Data reported for both male and female IDUs	<1% IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	<1%
Data reported for male IDUs	
Adjustments	
Final/Adjusted data	
Data reported for female IDUs	
Adjustments	
Final/Adjusted data	

**T&C: All documents reviewed**

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Bukowska, B., et al, and Reitox National Focal Point (2006). Poland: New Developments, Trends and In-depth Information on Selected Issues. National Report to the EMCDDA.

International Harm Reduction Development Program (2008). Harm reduction developments 2008. New York.

Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

**5. Anti-retro-viral (ARV) treatment****ARV 1: Number of sites providing ARV treatment**

<b>Data reported</b>	19 sites + prisons		
<b>Year of reported data</b>	2009		
<b>Reference</b>	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	> 19		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	27 287 709 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>HIV among IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0.24	8.90	17.68
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
<b>Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Number of ARV treatment sites per 1000 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

## ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	1372 IDUs on ART in 2007		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments	Assumed single point in time		
Final/Adjusted data (to be used as indicator numerator)	1372		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 131 254 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
HIV among IDU prevalence estimate (%)	Low	Mid	High
	0.24	8.90	17.68
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	NK	NK	NK

## ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	No restrictions
Year of reported data	2007
Reference	Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

**ARV: All documents reviewed**

Aceijas, C., E. Oppenheimer, et al. (2006). "Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5")." *Addiction* 101(9): 1246-53.

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Bukowska, B., et al, and Reitox National Focal Point (2006). Poland: New Developments, Trends and In-depth Information on Selected Issues. National Report to the EMCDDA.

Donoghoe, M. C., A. R. Bollerup, et al. (2007). "Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004." *International Journal of Drug Policy* 18(4): 271-80.

European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

National AIDS Center - Poland (2008). "Summary of the HIV/AIDS epidemic in Poland." from [http://aids.gov.pl/index\\_en.php?page=epidemiologia&act=pl&id=2](http://aids.gov.pl/index_en.php?page=epidemiologia&act=pl&id=2).

Reitox National Focal Point (2008). Poland - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

## 6. Condoms

### Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	Condoms are distributed at low threshold NSP facilities.
Year	2007
Reference	Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

### Condoms 2: Number of sites distributing condoms to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2007		
Reference	Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 131 254 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High
	NK	NK	NK

## Condoms 4: Number of condoms distributed to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2007		
Reference	Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	27 131 254 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

## Condoms: All documents reviewed

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.

Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

Grzegorz Wodowski Poland (2008). The METHWORK program. Reference Group to the UN on HIV and Injecting Drug Use. Krakow.

Harm Reduction Center (2008). Statistics from period 1996-2008, Krakow.

Ptaszek, G. (2007). HIV/AIDS: the Polish policy 1985-2005. Warsaw, National AIDS Centre.